| Literature DB >> 35408647 |
Anabela Veiga1,2,3, Rui Magalhães1, Marta M Duarte1, Juliana R Dias3, Nuno M Alves4, Ana Rita Costa-Pinto5,6, Filipa Castro2,3, Fernando Rocha2,3, Ana L Oliveira1.
Abstract
Calcium plays an important role in barrier function repair and skin homeostasis. In particular, calcium phosphates (CaPs) are well established materials for biomedical engineering due to their biocompatibility. To generate biomaterials with a more complete set of biological properties, previously discarded silk sericin (SS) has been recovered and used as a template to grow CaPs. Crucial characteristics for skin applications, such as antibacterial activity, can be further enhanced by doping CaPs with cerium (Ce) ions. The effectiveness of cell attachment and growth on the materials highly depends on their morphology, particle size distribution, and chemical composition. These characteristics can be tailored through the application of oscillatory flow technology, which provides precise mixing control of the reaction medium. Thus, in the present work, CaP/SS and CaP/SS/Ce particles were fabricated for the first time using a modular oscillatory flow plate reactor (MOFPR) in a continuous mode. Furthermore, the biological behavior of both these composites and of previously produced pure CaPs was assessed using human dermal fibroblasts (HDFs). It was demonstrated that both CaP based with plate-shaped nanoparticles and CaP-SS-based composites significantly improved cell viability and proliferation over time. The results obtained represent a first step towards the reinvention of CaPs for skin engineering.Entities:
Keywords: calcium phosphate-based materials (CaP); cerium (Ce); human dermal fibroblasts (HDFs); modular oscillatory flow plate reactor (MOPR); silk sericin (SS); skin regeneration
Mesh:
Substances:
Year: 2022 PMID: 35408647 PMCID: PMC9000890 DOI: 10.3390/molecules27072249
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Identification of the functional groups present in the FTIR spectra of the samples synthesized.
| Wavenumber | HAp Reference | Commercial HAp | Sericin | CaP1-Nano | CaP2-Nano/Micro | CaP3-Micro | CaP-SS | CaP-SS-Ce |
|---|---|---|---|---|---|---|---|---|
|
| 1087, | 1090 | - | - | - | - | - | - |
| 1032, | 1024 | 1020 | 1020 | 1020 | 1023 | |||
| 962, | 962 | 961 | 960 | 961 | - | |||
| 602, | 600 | 600 | 597 | 600 | 600 | |||
| 561, | 561 | 558 | 561 | 559 | 530 | |||
| 472, | - | - | - | - | - | |||
|
| - | - | - | - | - | 983 | - | - |
| 1053 | ||||||||
|
| - | - | - | - | - | 574 | - | - |
| 541 | ||||||||
|
| 875 | 874 | - | 866 | 875 | 869 | 865 | - |
| 1410 | 1418 | - | - | - | ||||
|
| 631 | 630 | - | - | - | - | - | - |
| 3572 | 3571 | - | - | - | - | - | ||
|
| - | - | - | - | - | 3533 | ||
| 3477 | ||||||||
| 3151 | ||||||||
|
| - | - | - | - | - | 1647 | - | - |
|
| - | - | - | - | - | 1205 | ||
| 1099 | ||||||||
|
| 777 | |||||||
| 653 | ||||||||
|
| - | - | 1657 | - | - | - | 1644 | 1644 |
|
| - | - | 1551 | - | - | - | - | - |
|
| - | - | 1251 | - | - | - | - | - |
Identification of the peaks present in the XRD patterns of the synthetized samples and reference CaPs.
| Sample | °2 Theta | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Miller Index | HAp Reference | Brushite (JCPDS 72-0713 | Commercial HAp | [ | CaP1-Nano | CaP2-Nano/Micro | CaP3-Micro | CaP-SS | CaP-SS-Ce |
| 020 | - | 11.71 | - | 11.71 | 11.70 | - | - | ||
| 121 | 20.62 | 21.00 | 21.04 | ||||||
| 104 | 23.47 | - | 23.53 | ||||||
| 002 | 25.79 | - | 26.09 | 25.90 | 25.95 | 26.07 | - | 25.96 | |
| 141 | - | 29.15 | - | 29.33 | 29.38 | ||||
| 211 | 31.08 | - | 32.08 | 31.86 | 31.78 | 31.64 | - | 31.77 | |
| 112 | 32.20 | 32.41 | 32.20 | 32.26 | 32.29 | 32.27 | |||
| 300 | 32.92 | 33.17 | 32.90 | 33.73 | - | 33.79 | |||
| 121 | - | 34.19 | - | 34.18 | 34.21 | ||||
| 222 | 36.49 | - | 36.57 | ||||||
| 310 | 39.81 | - | 40.12 | 39.86 | 39.88 | 39.78 | - | 40.59 | |
| 152 | - | 41.01 | - | 41.67 | 41.69 | ||||
| 222 | 46.69 | - | 46.95 | 46.69 | 46.67 | 46.61 | - | 46.81 | |
| 213 | 49.43 | 49.74 | 48.16 | 49.82 | 50.31 | 49.60 | |||
| 143 | - | 50.75 | - | 50.25 | - | ||||
| 004 | 53.21 | - | 53.43 | 53.27 | 53.37 | 53.56 | - | 53.51 | |
Figure 1XRD patterns of the experimental conditions analyzed.
EDX analysis to the CaP and CaP composites produced and Ca/P molar ratio.
| Calcium-Based Material | Oxygen (O) | Phosphate (P) | Calcium (Ca) | Cerium (Ce) | Ca/P Molar Ratio | ||||
|---|---|---|---|---|---|---|---|---|---|
| Weight (%) | Atomic (%) | Weight (%) | Atomic (%) | Weight (%) | Atomic (%) | Weight (%) | Atomic (%) | ||
| Commercial HAp | 40.26 | 60.68 | 19.09 | 14.86 | 40.64 | 24.45 | - | ||
| CaP1-nano | 40.76 | 60.97 | 20.87 | 16.10 | 38.38 | 22.92 | 1.68 | ||
| CaP2-nano/micro | 35.19 | 55.24 | 22.45 | 18.20 | 42.37 | 26.44 | 1.69 | ||
| CaP3-micro | 45.75 | 65.32 | 22.37 | 16.50 | 31.88 | 18.17 | 1.23 | ||
| CaP-SS | 41.30 | 61.42 | 21.42 | 16.44 | 37.28 | 22.15 | 1.65 | ||
| CaP-SS-Ce | 30.38 | 58.78 | 18.67 | 18.65 | 20.00 | 15.44 | 30.51 | 6.74 | 1.01 |
Figure 2TEM images of the particles produced.
Figure 3SEM images of the produced particles.
Figure 4Particle size distribution in (A) number and (B) volume.
Figure 5Cell viability and proliferation measured by (A) MTT assay and (B) DNA quantification, for HDFs cultured in direct contact with synthesized and commercial HAp particles, for 1, 3, and 7 days of culture (** p < 0.01, **** p < 0.0001).
Cell viability after 7 days of cell culture (Equation (1)).
| Experimental Conditions | Cell Viability (%) |
|---|---|
| Commercial HAp | 87.4 ± 27.5 |
| CaP1-nano | 90.9 ± 21.26 |
| CaP2-nano/micro | 79.4 ± 18.88 |
| CaP3-micro | 67.7 ± 2.26 |
| CaP-SS | 90.5 ± 28.74 |
| CaP-SS-Ce | 96.8 ± 24.56 |
Significance level for DNA quantification after 7 days of cell culture (** p < 0.01, *** p < 0.001, **** p < 0.0001, ns-not significant).
| CaP1-Nano | CaP2-Nano/Micro | CaP3-Micro | CaP-SS | CaP-SS-Ce | Control | |
|---|---|---|---|---|---|---|
| Commercial HAp | ns | ** | ns | **** | **** | **** |
| CaP1-nano | *** | ns | **** | **** | **** | |
| CaP2-nano/micro | *** | ns | ns | ns | ||
| CaP3-micro | **** | **** | **** | |||
| CaP-SS | ns | ns | ||||
| CaP-SS-Ce | ns | |||||
Figure 6SEM images illustrating the morphology, distribution, and proliferation of HDFs cultured in direct contact with the produced Ca-based particles and commercially available HAp for 1, 3, and 7 days of culture.
Figure 7SEM images using the Z-contrast mode for CaP-SS-Ce particles and EDX spectra after 7 days of culture.
Figure 8Confocal images illustrating the morphology, distribution, and proliferation of the HDFs’ nucleus and cytoskeleton cultured in direct contact with the produced Ca-based particles and commercially available HAp for 1 and 7 days of culture.
Figure 9Preliminary antibacterial test on CaP-SS-Ce particles using (A) Gram+ (Staphylococcus aureus) (B) Gram– (Escherichia coli) bacteria and 20 µL of a particle suspension in Ringer’s solution with (1) 50 µg/mL, (2) 12,500 µg/mL.
Figure 10Experimental set-up adapted from [62].
CaPs and CaP/sericin-based composites produced in the MOFPR. Silk sericin and cerium concentrations used were based on published works [3,31].
| Experimental Conditions | Initial Reagents Concentration | Description | Physicochemical Characteristics | Frequency (Hz) | Amplitude (mm) | [Sericin] g/L | [Cerium] g/L |
|---|---|---|---|---|---|---|---|
| 1. | CaCl2.2H2O (0.02 M) | CaP1-nano | HAp nanoparticles | 1.9 | 4 | - | - |
| 2. | Na2HPO4 (0.012 M) | CaP2-nano/micro | HAp nano and microparticles | 4 | 4 | ||
| 3. | CaCl2.2H2O (0.2 M) | CaP3-micro | Brushite particles | 1.9 | 4 | ||
| Na2HPO4 (0.12 M) | |||||||
| 4. | CaCl2.2H2O (0.02 M) | CaP-SS | To evaluate | 0.1 | |||
| 5. | Na2HPO4 (0.012 M) | CaP-SS-Ce | 0.1 | 0.4 |